Previous results have indicated that mac25/angiomodulin (AGM) is expressed in lymph node (LN) high endothelial venules (HEV), the specialized venules that support ef®cient lymphocyte transendothelial migration. How mac25/AGM's endothelial expression pattern is regulated in situ remains unknown. Here, we demonstrate that in mouse LN blood vessels, including HEV, mac25/ AGM is localized, unlike previous reports, not to the luminal or lateral regions bordering the endothelial cells (EC), but exclusively to the basal lamina that is in direct association with EC. In the spleen, mac25/AGM was expressed in the vascular basal lamina, in direct association with smooth muscle cells and pericytes, but not with EC. In addition, we report herein that mac25/AGM is an inducible marker for activated EC. In in¯amed tissues, mac25/AGM expression was strongly induced in the abluminal region of blood vessels. In vitro, mac25/AGM was readily induced in EC upon activation with pro-in¯ammatory cytokines such as tumor necrosis factor-a, indicating that mac25/AGM is an activated EC marker. mac25/AGM binds vascular endothelial growth factor and, together with its strict abluminal localization, it is suggested that mac25/AGM has a speci®c function(s) in the subendothelium of activated blood vessels such as capturing humoral factors produced in the vicinity of HEV.
Introduction
The endothelium serves as a critical interface between the blood and the tissue parenchyma, regulating a number of processes, such as vascular permeability, blood¯ow, thrombogenesis, hematogenous tumor metastasis and leukocyte extravasation (1) . Although various vascular endothelial cells (EC) share certain functions, there exists a considerable diversity of specialized functions that depend on the types of EC present and the properties of the underlying tissue. Nevertheless, the molecular mechanisms regulating the functional diversity of EC remain largely unknown (1, 2) .
One specialized type of microvasculature that has received much attention is the high endothelial venules (HEV) of the secondary lymphoid organs. The HEV, which are lined by morphologically and functionally distinctive EC, serve as the entrance for circulating lymphocytes into the parenchyma of the secondary lymphoid organs, such as the lymph nodes (LN), tonsils and Peyer's patches (PP), allowing lymphocytes to migrate and respond to antigens within the organ. The HEV mediate a highly selective lymphocyte recruitment process, termed lymphocyte homing, that involves a cascade of speci®c steps: lymphocyte tethering, rolling and ®rm adhesion to the luminal surface, and, ®nally, transendothelial migration across the HEV (3, 4) . While there has been a great deal of progress in elucidating the adhesion molecules and chemokines involved in the cascade reactions, much remains unknown about the mechanisms by which the speci®c phenotype and functional properties of HEV are maintained. To investigate these issues, we have constructed a 3¢-directed cDNA library from the mouse LN HEV cells expressing the peripheral lymph node addressins (PNAd) or mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and reported expression pro®les of the active genes in HEV (5, 6 ). Among the highly expressed genes in HEV, a mouse homologue of mac25/insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) (7)/angiomodulin (AGM) (8)/prostacyclin stimulating factor (PSF) (9) has been identi®ed.
The cDNA encoding mac25/AGM was ®rst cloned from human brain leptomeningeal cells (10) . Essentially the same cDNA has been cloned from human ®broblasts as PSF, which stimulates prostacyclin (PGI 2 ) production in vascular EC (9, 11) . PGI 2 is a potent vasodilator and an inhibitor of platelet adhesion and aggregation, contributing to the vascular homeostasis (1, 11) . Human mac25/AGM was also isolated from the conditioned medium of a human bladder carcinoma cell line and found to be a secretory glycoprotein of~30 kDa (12) . This protein has the ability to regulate cell adhesion to and spreading on plastic plates and various extracellular matrix (ECM) components, and hence has also been designated as the tumor-derived adhesion factor [TAF (8) ; later renamed as AGM (13) ]. Interestingly, mac25/AGM is also expressed in tumor vessels (8, 14) . These observations collectively indicate that mac25/AGM has diverse functions, while its precise role in individual tissues remains unknown.
In the present study, to gain further insight into the functional properties of mac25/AGM, we generated a biologically active recombinant mouse mac25/AGM using the baculovirus-mediated expression system, raised a speci®c polyclonal antibody (pAb) against it, and performed immunohistochemistry using both light and electron microscopy. We found that mac25/ AGM localizes strictly to the basal side of small blood vessels including the HEV in mouse lymphoid tissues, in sharp contrast to the luminal and lateral expression of mac25/AGM in the HEV of human tonsils (15) . We have also demonstrated that the endothelial expression of mac25/AGM is induced in vivo in in¯amed tissues and in vitro by a pro-in¯ammatory cytokine tumor necrosis factor (TNF)-a. Hence, an apparently multifunctional protein mac25/AGM is an inducible marker for activated EC. In addition, mac25/AGM can bind vascular endothelial growth factor (VEGF) and, together with its strict abluminal localization, it is implied to function in the subendothelium of activated blood vessels by capturing humoral factors produced in the vicinity of HEV.
Methods

Animals
All animal experiments were performed under an experimental protocol approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine. C57BL/6 mice were purchased from Japan SLC (Hamamatsu, Japan) and used at 10±12 weeks old. BALB/c mice were purchased from Clea Japan (Tokyo, Japan) and used at 9±12 weeks old. New Zealand White female 3-monthold rabbits were purchased from Kiwa Animal (Wakayama, Japan).
Reagents
Recombinant mouse VEGF 164 , TNF-a, IFN-g, IL-1b and IL-6 were purchased from R & D Systems (Minneapolis, MN). Other biochemical reagents were purchased from Sigma-Aldrich (St Louis, MO), unless otherwise speci®ed. The following antibodies were purchased: horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (H + L) (American Qualex, San Clemente, CA), rhodamine-conjugated donkey anti-rabbit IgG (Chemicon, Temecula, CA), anti-mouse collagen IV pAb (Dako, Tokyo, Japan), FITC-conjugated and biotin-conjugated goat anti-rat IgG + M (Southern Biotechnology Associates, Birmingham, AL), FITC-conjugated mAb for mouse CD31 (PECAM-1, clone MEC13.3; BD PharMingen, San Diego, CA), mouse CD106 (VCAM-1, clone 429; BD PharMingen), mouse CD4 (clone RM4-5; BD PharMingen), anti-polyhistidine-, antimyc-epitope (C-term) mAb (Invitrogen, Carlsbad, CA), and anti-mouse VEGF mAb (PeproTech, Rocky Hill, NJ). The MECA-79 mAb (16) was kindly provided by Dr E. C. Butcher (Stanford University, CA). Biotin or FITC conjugation of antibodies was performed using standard procedures.
Cell culture
The mouse brain EC line bEnd.3 (17) (obtained from ATCC, Rockville, MD; CRL-2299) was maintained in DMEM (SigmaAldrich) supplemented with 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 10 mM HEPES, 10 mM NaHCO 3 , 2 mM L-glutamine, 1% (v/v) 100 Q non-essential amino acids (Gibco/ BRL, Grand Island, NY), 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco/BRL) and 10% heat-inactivated FCS (Dainippon Pharmaceutical, Osaka, Japan). Primary calf pulmonary artery EC (CPAEC; Dainippon Pharmaceutical) were subcultured as described previously (18) . The EC were passaged every 3±4 days and used at passages 3±8. Sf9 insect cells (Invitrogen) were maintained at 27°C in Grace's insect medium (Invitrogen). High Five cells (Invitrogen) were maintained at 27°C in EX-CELL 400 medium (JRH BioScience, Lenexa, KS). The culture medium for the insect cells was supplemented with 10% FCS, 100 U/ml penicillin and 100 mg/ ml streptomycin.
Preparation of recombinant mouse mac25/AGM and generation of pAb against mac25/AGM The full-length mac25/AGM cDNA (GenBank AB012886) in the plasmid pBluescriptSKII-mac25 (19) , kindly provided by Dr Y. Hayashizaki (RIKEN, Tsukuba, Japan), was excised out with BsgI and XcmI, and inserted into the corresponding multiple cloning site of the plasmid pcDNA3.1/Myc-His(+) (Invitrogen). Using the resulting plasmid as a template, the SpeI±XhoI fragment containing the mac25/AGM cDNA, polyhistidine and myc epitopes was generated by PCR with the primers, 5¢-GGACTAGTTAAGCTTATGATGGAGCGGC-3¢ and 5¢-CCG-CTCGAGGCTGATCAGCGGGTTTAAACTCAATG-3¢, followed by digestion with SpeI and XhoI. The resulting fragment was subcloned into the corresponding multiple cloning site of the pFastBac1 baculovirus transfer vector (Invitrogen). For largescale production of the recombinant mac25/AGM protein, the Bac-to-Bac baculovirus expression system (Invitrogen) was used according to the manufacturer's instructions. The culture supernatant of the infected High Five cells was collected after 36 h of infection, and the secreted recombinant mac25/AGM with a molecular size of~34 kDa was puri®ed to homogeneity (Fig. 1A ) by af®nity chromatography with the Ni 2+ -based Probond resin (Invitrogen) and gel ®ltration chromatography (Sephadex-G200; Amersham, Little Chalfont, UK), and ®nally concentrated by ultra®ltration (CentriPlus YM-10; Millipore, Bedford, MA). The N-terminal sequence of the puri®ed protein (Ser-Ser-Ser-Asp-Ala-Cys-Gly-Pro-Cys-Val) was found to be identical to that of mature mouse mac25/AGM (19) , indicating that it was a mature full-length form of mac25/AGM. Addition of the recombinant mac25/AGM to cultured EC (CPAEC) resulted in the generation of a stable metabolite of PGI 2 , 6-keto-PGF 1 a, in a dose-dependent manner as has been reported previously (11) (Fig. 1B) , indicating that the recombinant mac25/AGM thus obtained was biologically active.
pAb was raised against the recombinant mac25/AGM protein by subcutaneous immunization of New Zealand White female rabbits with the puri®ed recombinant mac25/ AGM (0.2 mg) emulsi®ed in complete (for the initial injection) or incomplete (for the booster injection) Freund's adjuvant. The polyclonal IgG was af®nity puri®ed from the immunized serum using a Protein G±Sepharose CL-4B (Amersham BioSciences) column and a recombinant mac25/AGM-conjugated column. The af®nity-puri®ed pAb as well as a commercially available anti-polyhistidine mAb successfully detected the myc-and polyhistidine-tagged 34-kDa recombinant mac25/AGM protein on Western blots (Fig. 1C, lanes 1 and 2) . It should be noted that the anti-mac25/AGM pAb speci®cally recognized the endogenous mac25/AGM produced by bEnd.3 cells (Fig. 1C, lane 3 ). Concerning the cross-reactivity of the pAb, we failed to detect its reactivity against human mac25/AGM that has high sequence homology (87%) to mouse mac25/ AGM (data not shown). Furthermore, this antibody failed to react other myc-, His-tagged recombinant proteins such as L-selectin that we generated (data not shown), further verifying its speci®city.
Immunohistochemistry
Immunostaining of frozen sections was performed as described previously (6) . Brie¯y, cryosections (8 mm) were ®xed in acetone and then in 4% paraformaldehyde (PFA)/PBS. The tissue sections were ®rst incubated with the anti-mac25/AGM pAb (1 mg/ml), followed by rhodamine-conjugated goat anti-rabbit IgG (H + L) (1:200) and secondly incubated with FITC-conjugated MECA-79 mAb (2 mg/ml) or FITC-conjugated anti-mouse CD31 mAb (2 mg/ml). In some experiments, the tissue sections were ®rst incubated with biotinylated antimac25/AGM pAb (1 mg/ml), followed by rhodamine± streptavidin (5 mg/ml; PharMingen), and then incubated with FITC-conjugated anti-mouse collagen IV pAb (1 mg/ml). For peroxidase detection, the tissue sections were ®rst incubated with the anti-mac25/AGM pAb (1 mg/ml), followed by HRPconjugated anti-rabbit IgG (H + L) (1 mg/ml) and developed with an Immunopure Metal Enhanced DAB Substrate kit (Pierce, Rockford, IL). In each experiment, a negative control study was done by omitting the primary antibody or by using an irrelevant isotype-and concentration-matched primary antibody. To con®rm the speci®city of the anti-mac25/AGM pAb, a 20-fold molar excess of the recombinant mac25/AGM was added. A myc-and polyhistidine-tagged mac25/ AGM was generated by the baculovirus-mediated protein expression system and puri®ed using a Ni 2+ -chelated af®nity column to homogeneity, which was con®rmed by SDS±PAGE with Coomassie brilliant blue staining. (B) The bioactivity of the recombinant mac25/AGM as PSF. PGI 2 production in CPAEC upon mac25/AGM stimulation was measured by competitive ELISA to detect its stable metabolite, 6-keto-PGF 1 a. mac25/AGM (1±60 mg/ ml, for 1 h) increased PGI 2 synthesis in a dose-dependent manner (n = 6 in each group). Bovine thrombin was used as positive control for PGI 2 induction. Data obtained are the mean T SD of three independent experiments. (C) Western blots of the mac25/AGM protein using various antibodies. The recombinant mac25/AGM (lanes 1 and 2) and the culture supernatant of bEnd.3 cells (lane 3) were subjected to SDS±PAGE, and electroblotted onto PVDF membranes. The blots were incubated with antibodies as indicated.
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Immunoelectron microscopy
Mice were perfused with a 4% PFA and 0.1% glutaraldehyde mixture in 0.1 M cacodylate buffer (pH 7.4) containing 5% sucrose. LN, PP and spleens were removed and further ®xed in the same ®xative at 4°C for 4 h, and then immersed in 10, 15 and ®nally 20% sucrose solutions. The tissues were then cut into 50-mm slices by a cryostat. Endogenous peroxidase in the slices was blocked by incubating them in a 0.5% sodium metaperiodate solution. The slices were then incubated with rabbit anti-mac25/AGM pAb (1 mg/ml) for 48 h at 4°C, followed by incubation with HRP±goat anti-rabbit IgG (H + L) (1 mg/ml). They were then ®xed with 2% glutaraldehyde for 10 min and incubated in a diaminobenzidine solution containing H 2 O 2 (DAB Reagent Set; KPL, Gaithersburg, MD). The DAB-reacted slices were post-®xed with 2% osmium tetroxide for 1 h and embedded in Epon 812 after dehydration in graded acetone solutions. Ultrathin sections were cut with an ultramicrotome (Ultracut, Reichert-Jung, Germany) at a thickness of~100 nm. The sections were left unstained or stained with uranyl acetate and examined with a transmission electron microscope (200CX; Jeol, Tokyo, Japan).
In¯ammation model
A chronic in¯ammation model with contact hypersensitivity was made as described previously (20) . In brief, BALB/c mice were sensitized on the ear skin with 0.5% dinitro¯uorobenzene (DNFB) and challenged repeatedly by applications of 0.2% DNFB on the same site every other day. Ear skin specimens were taken 48 h after the second challenge and examined by immunohistochemistry. Two independent experiments with three mice in each group were performed.
In vitro induction of mac25/AGM upon cytokine treatment Quiescent bEnd.3 cells were treated with various cytokines for the indicated periods, then the conditioned medium was collected, concentrated by ultracentrifugation, subjected to SDS±PAGE and transferred to a polyvinylidene¯uoride (PVDF) membrane (Millipore). The blot was probed with antimac25/AGM pAb (0.5 mg/ml), followed by HRP±goat antirabbit IgG (H + L) (0.5 mg/ml). The blot was then developed with the ECL Western blotting detection reagents (Amersham). Densitometry was performed using NIH Image analysis software. For¯ow cytometry, cells were incubated with FITCconjugated anti-VCAM-1 mAb (5 mg/ml) and analyzed by an Epics-XL¯ow cytometer (Coulter, Hialeah, FL). Expression of VCAM-1 was assessed at 4 and 24 h after TNF-a stimulation. For RT-PCR, the total RNA from bEnd.3 cells was reverse transcribed with an oligo-dT 18 primer. A speci®c oligonucleotide sense primer 5¢-ATCACTCTGGAGTTCAGC-3¢ and an antisense primer 5¢-AAGAGAAGTGTGTCAGGC-3¢ were used for mac25/AGM, and 5¢-ATGGATGACGATATCGCT-3¢ and 5¢-ATGAGGTAGTCTGTCAGGT-3¢ were used for b-actin (5).
mac25/AGM binding to VEGF
For the detection of the interaction between mac25/AGM and VEGF, the recombinant mac25/AGM (1 mg/ml) was immobilized onto 96-well microtiter plates (Sumilon H; Sumitomo Bakelite, Tokyo, Japan) at 4°C (50 ml/well). The wells were blocked with 3% BSA and incubated with varying concentrations of VEGF. VEGF bound to mac25/AGM was detected with anti-VEGF mAb and HRP-conjugated anti-rabbit IgG. To quantify the reaction, o-phenylenediamine was added and the optical density at 490 nm was read in a microtiter plate reader (InterMed, Tokyo, Japan). As control experiments, BSA (1 mg/ml) or recombinant myc-, His-tagged human L-selectin (1 mg/ml) (6) was immobilized instead of the recombinant mac25/AGM.
Results
mac25/AGM is constitutively expressed in the abluminal region of LN HEV
We carried out immunohistochemical analyses of mouse LN, PP and spleen using the anti-mac25/AGM pAb. In accordance with previous reports (5, 6, 15) , strong expression of mac25/ AGM was observed in the HEV of all the peripheral LN tested, while moderate to weak expression was also observed in non-HEV-type blood vessels of mesenteric LN ( Fig. 2A and B) . Double immuno¯uorescence staining with a pan-EC marker anti-CD31 (PECAM-1) and the anti-mac25/AGM pAb con®rmed that the majority of the blood vessels in LN were positive for mac25/AGM expression (Fig. 2C±E) . Strong expression of mac25/AGM by HEV was also observed in the cervical and axillary LN as well as in the PP (data not shown).
While the above results are apparently concordant with those reported by Girard et al. (15) , a closer investigation revealed that the pattern of expression of mac25/AGM in mouse HEV is quite different from that reported previously, i.e. mac25/AGM preferentially accumulated on the abluminal side of these blood vessels. Double immuno¯uorescence staining using the anti-mac25/AGM pAb and the MECA-79 mAb, which speci®cally reacts with PNAd (16), showed that the mac25/ AGM-speci®c immunoreactivity was preferentially associated with the abluminal region of the HEV (Fig. 2G) , whereas MECA-79's immunoreactive product was seen throughout the entire cell body of the HEV cells (Fig. 2F) . A merged view of the mac25/AGM and MECA-79 staining clearly illustrates the abluminal accumulation of mac25/AGM in the HEV (Fig. 2H) . In addition, two-color immunostaining with the anti-mac25/ AGM pAb and an antibody against collagen type IV showed the co-localization of mac25/AGM and collagen IV, which is also present on the abluminal side of HEV (Fig. 2I±K) . In all the staining experiments described above, an irrelevant primary antibody or secondary antibody alone gave no positive signal (data not shown), verifying the speci®city of the observations obtained above.
To con®rm the abluminal pattern of mac25/AGM expression in mouse HEV, we then performed immunoelectron microscopic analysis using the anti-mac25/AGM pAb. As shown in Fig. 3(A and B) , the immunoreactive mac25/AGM densely accumulated in the basal lamina just beneath the HEV cells of peripheral LN and was uniformly distributed throughout the basal surface, but almost excluded from the luminal surface of the HEV. A similar staining pattern was observed in PP ( Fig. 3C  and D) . In contrast, in the spleen, where no HEV are seen, mac25/AGM was speci®cally localized to the basal lamina just beneath the smooth muscle cells of the blood vessels and no positive signal was associated with the vascular EC (Fig. 3E and F). It could be that mac25/AGM is produced by smooth muscle cells and/or pericytes, but not by EC in the¯at endothelial blood vessels of the spleen. These results con®rm and extend our light microscopy observations that in HEV, mac25/AGM shows a restricted localization to the abluminal side of blood vessels.
mac25/AGM is induced in in¯amed blood vessels
Because a few molecules, such as PNAd (16), MAdCAM-1 (21,22) and vascular adhesion protein-1 (23,24), which are expressed preferentially in HEV under physiological conditions, are often observed in blood vessels in chronically in¯amed tissues, we examined whether mac25/AGM is also inducible in in¯ammatory lesions. In chronically in¯amed skin lesions induced by repeated challenges with DNFB, mac25/ AGM expression was clearly observed in the dermal blood vessels (Fig. 4A, C and H) . In sharp contrast, mac25/AGM was only weakly, if at all, detected in the blood vessels of shamsensitized (Fig. 4B, D and E) or unsensitized (data not shown) skin. Double staining with anti-CD31 mAb and anti-mac25/ AGM pAb revealed that mac25/AGM was expressed in most blood vessels in the dermis of chronically in¯amed DNFBsensitized skin (Fig. 4H±J) , particularly on the abluminal side of dermal blood vessels. These results suggest that mac25/ AGM is inducible by in¯ammatory stimuli and that the pattern of expression in in¯amed venules is quite similar to that observed in HEV.
mac25/AGM is induced upon stimulation with in¯ammatory mediators in vitro
While we found that mac25/AGM is induced in in¯amed blood vessels, previous reports by others indicate that it is inducible in non-EC types (11,25±27). We therefore wished to determine whether mac25/AGM could be induced in EC in vitro using a mouse endothelioma cell line, bEnd.3. After treatment with TNF-a for 24 h, bEnd.3 cells strongly expressed VCAM-1 (Fig. 5A ) and produced mRNA encoding mac25/AGM (Fig. 5B) . Examination of the culture supernatant of the bEnd.3 cells revealed that the mac25/AGM protein was produced by the cells in a manner dependent on the time of incubation and dose of TNF-a used (Fig. 5C ). While none of the stimulators we used, including TNF-a, IL-1b, IL-6, VEGF, lipopolysaccharide, phorbol myristate acetate and IFN-g, induced detectable levels of mac25/AGM protein expression at 4 h after stimulation (data not shown), at 24 h of stimulation, TNF-a induced a prominent production of mac25/AGM dose dependently and other stimulators, such as VEGF and IFN-g, only slightly up-regulated the mac25/AGM production. After 48 h, TNF-a induced a greater production of mac25/AGM. These results indicate that TNF-a is particularly potent as an inducer of endothelial mac25/AGM.
mac25/AGM binds VEGF
Because mac25/AGM's expression is localized to the abluminal region of HEV that are highly metabolically active (28), we thought it likely that mac25/AGM captures angiogenic factors such as VEGF. When VEGF was added to immobilized mac25/ AGM, it was found that VEGF binds to mac25/AGM dose dependently, and the binding was saturable at 0.3 mg/ml of VEGF (Fig. 6) . VEGF did not bind to a myc-, His-tagged control protein, the recombinant human L-selectin, indicating the speci®city of the VEGF binding to mac25/AGM. These results indicate that mac25/AGM has the ability to interact with VEGF, if secreted locally, in vivo.
Discussion
Recent studies from our laboratory and others have demonstrated that mac25/AGM is abundantly expressed in HEV cells (5,6,15) . The mouse homologue of mac25/AGM shares 87.5% mac25/AGM expression in HEV and activated EC 1277 nucleotide identity and 94.4% similarity with its human counterpart and is implicated in tumor cell growth (19, 29) . Although Northern analysis has indicated that mac25/AGM is distributed ubiquitously in almost all mouse and human tissues (5,7), several histochemical studies using anti-peptide antibodies in human tissues (30) have shown that its distribution in each organ is restricted to certain components of the tissue, such as neurons, muscles, epithelial cilia and vascular endothelia. However, mac25/AGM's de®nite function(s) in situ remains largely unknown.
In this study, we generated a recombinant mac25/AGM using the baculovirus expression system and raised a speci®c antibody (Fig. 1) to investigate the tissue localization of mac25/AGM in detail. One of the noteworthy ®ndings of our study is the dense accumulation of mac25/AGM protein in the basal lamina of HEV (Figs 2 and 3) . In LN and PP, mac25/AGM localized strictly to the HEV's basal lamina in direct association with EC, whereas in the spleen, mac25/AGM localized to the basal lamina in direct association with vascular smooth muscle cells, but not the EC. In all the lymphoid tissues tested, mac25/ AGM was found on the abluminal side of blood vessels and was generally excluded from the luminal surface. These results are in sharp contrast to the study by Girard et al. (15) , in which they reported a preferential localization of mac25/AGM to the luminal surface of HEV, particularly on the microvillous processes near the HEV junctions in human tonsils. This discrepancy may be explained in part by the fact that human tonsils are often exposed to microbes, whereas the LN of speci®c pathogen-free mice are not. However, deliberate antigenic challenges to the LN did not alter the expression pattern signi®cantly (T. Usui, unpublished observation) and, hence, this possibility is not very likely. Another possibility is that the discrepancy is due to the difference in the animal species used, but our preliminary study with a polyclonal anti- human mac25/AGM antibody (kindly provided by Dr R. G. Rosenfeld) showed strong abluminal staining of HEV on the frozen sections of the human cervical LN (T. Usui, unpublished observation). Therefore, a simple difference in the animal species may not account for the discrepancy. It is also possible that a difference in the ®ne speci®city of the antibodies used may partly account for the discrepancy in the results. For instance, certain epitopes on mac25/AGM may be immunologically cryptic and not readily detected under certain situations.
Concerning the biological signi®cance of the abluminal localization of mac25/AGM, it is of note that mac25/AGM can interact with various ECM components (8, 13) and VEGF (Fig. 6) . Also, mac25/AGM has been reported to regulate cell adhesion (8) and to promote the production of the potent vasodilator PGI 2 in EC (9, 11) . Therefore, one may speculate that the abluminal localization helps mac25/AGM play multiple roles regulating the HEV's functions, e.g. by sequestering and presenting various humoral factors to the HEV, allowing lymphocytes to transit through and to detach from the substratum so that they can migrate further into the parenchymal compartment, and/or relaxing the vascular tonus to decrease the local blood¯ow and to alter the lymphocyte migration across the HEV, although further experimental veri®cation will be required to resolve these issues.
We demonstrated for the ®rst time in the present study the inducible expression of mac25/AGM in in¯amed vessels in vivo (Fig. 4) . Consistently, mac25/AGM production was induced in EC by a pro-in¯ammatory cytokine TNF-a in vitro (Fig. 5) . TNF-a increased mac25/AGM secretion from the mouse EC line bEnd.3 in a time-and dose-dependent manner, and this induction was also observed at the transcriptional level (Fig. 5) . TNF-a is the principal cytokine produced by activated T cells to induce cell-mediated immune responses and activates nearby EC to enlist their participation in the immune response (31) . The TNF-a-dependent mac25/AGM synthesis was observed at doses that modify other activities of bEnd.3 cells, such as the up-regulation of VCAM-1 (Fig. 5) , indicating its physiological relevance. Taking into account the known mac25/AGM activities, its induction by a pro-in¯ammatory cytokine appears to be a plausible mechanism for regulating the vascular phenotype in immunological events.
TNF-a up-regulates various pro-in¯ammatory molecules, such as chemokines and cell adhesion molecules, in an NFkB-dependent fashion (32); however, a recent report on the characterization of the murine mac25/AGM gene revealed no NF-kB site in its promotor region (33) . In accordance with this report, none of the NF-kB-speci®c inhibitors we tested suppressed the TNF-a-dependent mac25/AGM induction signi®cantly (T. Usui, unpublished observation). Given that a number of factors have been reported to contribute to the mac25/AGM up-regulation (11,25±27), molecules other than pro-in¯ammatory cytokines may also contribute to the in¯am-mation-induced up-regulation of mac25/AGM in EC. With respect to the high expression of mac25/AGM in HEV, although TNF-a signals can be detected in areas near the HEV, and mRNAs encoding TNF receptor (R)-I and TNFR-II respectively, are also expressed in puri®ed HEV cells (T. Usui, unpublished observation), it is still unclear whether the TNF± TNFR pathway actually plays a role in the mac25/AGM's upregulation in HEV in situ.
It should be noted that HEV cells, in¯amed endothelium and tumor-associated endothelium (14) , all of which are apparently activated and abundantly express mac25/AGM, share at least one property; speci®cally, an increased vascular permeability. However, our antibody did not inhibit any of the reported functions of mac25/AGM, including the ability to induce prostacyclin, and we were also unable to induce an increased endothelial permeability in vitro with the recombinant mouse mac25/AGM (data not shown); thus, we could not investigate this issue further.
Concerning the biological relevance of mac25/AGM±VEGF interaction, we have attempted to detect the mac25/AGM± VEGF interaction in situ without success, i.e. we could not detect the expression of VEGF in lymph nodes by immunohistochemistry. However, the observation that HEV show rapid and strong neoangiogenesis in in¯ammatory situations (34, 35) indicates that HEV are highly sensitive to angiogenic factors such as VEGF in certain situations. Therefore, in the absence of in vivo data, we currently speculate that mac25/AGM can capture and present VEGF to its receptor in situ, if VEGF is produced locally.
In summary, we herein demonstrated the strict abluminal localization of mac25/AGM in activated endothelia, such as LN HEV cells and the EC in in¯amed blood vessels using an antimac25/AGM pAb that we generated. While mac25/AGM is apparently absent in the blood vessels of normal tissues, it was found to be readily up-regulated in in¯amed vessels in vivo, and also in vitro in response to pro-in¯ammatory cytokines, indicating that mac25/AGM is a novel marker of activated EC. Prominent binding of mac25/AGM with VEGF together with the restricted subendothelial localization of 
